XVIP.Y Stock Overview
A medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Xvivo Perfusion AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 10.67 |
52 Week High | SEK 12.97 |
52 Week Low | SEK 7.34 |
Beta | 2.15 |
1 Month Change | 0% |
3 Month Change | -15.25% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 166.75% |
Recent News & Updates
Recent updates
Shareholder Returns
XVIP.Y | US Medical Equipment | US Market | |
---|---|---|---|
7D | 0% | -1.2% | -2.7% |
1Y | n/a | 10.0% | 23.4% |
Return vs Industry: Insufficient data to determine how XVIP.Y performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how XVIP.Y performed against the US Market.
Price Volatility
XVIP.Y volatility | |
---|---|
XVIP.Y Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XVIP.Y's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine XVIP.Y's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 161 | Christoffer Rosenblad | www.xvivogroup.com |
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.
Xvivo Perfusion AB (publ) Fundamentals Summary
XVIP.Y fundamental statistics | |
---|---|
Market cap | US$1.33b |
Earnings (TTM) | US$18.51m |
Revenue (TTM) | US$68.01m |
71.9x
P/E Ratio19.6x
P/S RatioIs XVIP.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XVIP.Y income statement (TTM) | |
---|---|
Revenue | SEK 750.59m |
Cost of Revenue | SEK 192.08m |
Gross Profit | SEK 558.52m |
Other Expenses | SEK 354.25m |
Earnings | SEK 204.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
Earnings per share (EPS) | 6.48 |
Gross Margin | 74.41% |
Net Profit Margin | 27.21% |
Debt/Equity Ratio | 0% |
How did XVIP.Y perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 19:38 |
End of Day Share Price | 2024/11/11 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xvivo Perfusion AB (publ) is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Dylan van Haaften | Bryan Garnier & Co |
Maria Vara Fernández | Bryan Garnier & Co |
Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |